InNexus Biotechnology, Inc.
February 14 2006 - 12:15PM
PR Newswire (US)
TSX.V: IXS, OTCBB: IXSBF VANCOUVER, Feb. 14 /PRNewswire-FirstCall/
-- InNexus Biotechnology, Inc. is pleased to announce that Dr.
Charles Morgan has been invited to speak at the BIO CEO &
Investor Conference, Waldorf Astoria Hotel, New York. Dr. Morgan's
presentation will take place in the Duke of Windsor Room at 1:30
PM. on February 15th. This presentation will be available on the
companies web site: http://www.innexusbiotech.com/ About BIO BIO
represents more than 1,100 biotechnology companies, academic
institutions, state biotechnology centers and related organizations
across the United States and 31 other nations. BIO members are
involved in the research and development of healthcare,
agricultural, industrial and environmental biotechnology products.
About InNexus InNexus is an innovative antibody-driven drug
development company that has developed two technology platforms,
SuperAntibody(TM) and TransMAbs(TM), which improve the potency of
existing antibody products while opening new markets and disease
applications. Both platforms utilize unique, novel and patented
methods and technologies of InNexus. InNexus is headquartered in
British Columbia, Canada and has its own in-house developmental
facilities. These development facilities provide validation of
protein and peptide discoveries, enabling InNexus (and its
strategic partners) to advance novel drug therapeutics and
diagnostics. To learn more about InNexus please visit
http://www.innexusbiotech.com/. This news release contains
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. These statements are not
historical facts and are subject to risks and uncertainties which
could cause actual results and the timing of certain events to
differ materially from those set forth in or implied herein
including, without limitation, risks associated with clinical
development, regulatory approvals, product commercialization,
intellectual property claims litigation and other risks associated
with the Company's proposed activities. On behalf of the Board of
Directors of InNexus Biotechnology, Inc. Dr. A. Charles Morgan
President To contact us: Telephone: (877) 990-8382 Fax: (425)
696-0068 Email: Investor Relations: Telephone: (866) 990-8382 or
1-888-271-0788 Email: The TSX Venture Exchange has neither approved
nor disapproved of the information contained herein. DATASOURCE:
InNexus Biotechnology, Inc. CONTACT: Telephone: (877) 990-8382,
Fax: (425) 696-0068, Email: ; Investor Relations: Telephone: (866)
990-8382 or 1-888-271-0788, Email:
Copyright